An update on Helicobacter pylori

Current Opinion in Gastroenterology

Volumn 12, Issue 1, 1996, Pages 62-67

  Nedrud, John G ^a   Czinn, Steven J ^b  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VACCINE;

BACTERIUM IDENTIFICATION; DISEASE TRANSMISSION; GASTRITIS; GASTROINTESTINAL DISEASE; GRAM NEGATIVE INFECTION; HELICOBACTER PYLORI; HUMAN; IMMUNOTHERAPY; PATHOGENESIS; PEPTIC ULCER; SHORT SURVEY; STOMACH CANCER;

EID: 0030004997     PISSN: 02671379     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001574-199601000-00012     Document Type: Short Survey

References (63)

1. The Eurogast Study Group: Epidemiology of, and risk factors for Helicobacter pylori infection among 3194 asymptomatic subjects in 17 populations. Gut 1994, 34:1672-1676.
2. NIH Consensus Conference: Helicobacter pylori in peptic ulcer disease. JAMA 1994, 272:65-69. This review highlights the findings of the National Institutes of Health consensus conference confirming that H. pylori is a risk factor for peptic ulcer disease and gastric cancer.
3. Malaty HM, Graham DY: Importance of childhood socioeconomic status on the current prevalence of Helicobacter pylori infection. Gut 1994, 35:742-745.
4. Webb PM, Knight T, Greaves S, Wilson A, Newell DG, Elder J, Forman D: Relation between infection with Helicobacter pylori and living conditions in childhood: evidence for person-to-person transmission In early life. BMJ 1994, 308:750-753.
5. International Agency for Research on Cancer, World Health Organization: Infection with Helicobacter pylori. In Schistosomes, Liver Flukes and Helicobacter pylori. Lyon: International Agency for Research on Cancer; 1994:177-241. An in-depth review of the evidence associating H. pylori infection with the development of gastric cancer.
6. Lynch DAF, Mapstone NP, Clarke AMT, Sobala GM, Jackson P, Morrison L, Dixon MF, Quirke P, Axon ATR: Cell proliferation in Helicobacter pylori associated gastritis and the effect of eradication therapy. Gut 1995, 36:346-350.
7. Lynch DAF, Mapstone NP, Clarke AMT, Jackson P, Dixon MF, Quirke P, Axon ATR: Cell proliferation in the gastric corpus in Helicobacter pylori associated gastritis and after gastric resection. Gut 1995, 36:351-353.
8. Greiner A, Marx A, Heesemann J, Leebmann J, Schmauber B, Muller-Hermelink HK: Idiotype identity of a MALT-type lymphoma and B cells In Helicobacter associated gastritis. Lab Invest 1994, 70:572-578. This important study suggests that H. pylori infection may be the primary event for the development of MALT lymphomas.
9. Weber DM, Dimopoulos MA, Anandu DP, Pugh WC, Steinbach G: Regression of gastric lymphoma of mucosa-associated lymphold tissue with antibiotic therapy for Helicobacter pylori. Gastroenterology 1994, 107:1835-1838.
10. Mendall M, Molineaux N, Levi J, Strachan D, Northfield T: Association of H. pylori with diminished adult height [abstract]. Gut 1994, 35(suppl 1):S4.
11. Raymond J, Bergeret M, Benhamou PH, Mensah K, Dupont C: A 2-year study of Helicobacter pylori in children. J Clin Microbiol 1994, 32:461-463.
12. Patel P, Carrington D, Strachan DP, Leatham E, Goggin P, Northfield TC, Mendall MA: Fibrinogen: a link between chronic infection and coronary heart disease. Lancet 1994, 343:1634-1635.
13. Mendall MA, Goggin PM, Molineaux N, Levy J, Toosy T, Strachan D, Camm AJ, Northfield TC: Relation of Helicobacter pylori infection and coronary heart disease. Br Heart J 1994, 71:437-439.
14. Handt LK, Fox JG, Dewirst FE, Fraser GJ, Paster BJ, Yan LL, Rozmiarek H, Rufo R, Stalis IH: Helicobacter pylori isolated from the domestic cat: public health implications. Infect Immun 1994, 62:2367-2374. This interesting report describing the isolation of H. pylori from cats has public health ramifications and may serve as a useful animal model.
15. Cutler AF, Havstad S, Ma CK, Blaser MJ, Perez-Perez GI, Schubert TT: Accuracy of invasive and noninvasive tests to diagnose Helicobacter pylori infection. Gastroenterology 1995, 109:136-141.
16. Tytgat GNJ: Treatments that impact favourably upon the eradication of Helicobacter pylori and ulcer recurrence [review]. Aliment Pharmacol Ther 1994, 8:359-368.
17. Labenz J, Rühl GH, Bertrams J, Börsch G: Medium- and high-dose omeprazole plus amoxicillin for eradication of Helicobacter pylori in duodenal ulcer disease. Dig Dis Sci 1994, 39:1483-1487.
18. Labenz J, Stolte M, Domian C, Bertrams J, Börsch G: High-dose omeprazole plus amoxicillin or clarithromycin cures Helicobacter pylori infection in duodenal ulcer disease. Digestion 1995, 56:14-20.
19. Logan RPH, Gummett PA, Schaufelberger HD, Greaves RRFH, Mendelson GM, Walker MM, Thomas PH, Baron JH, Misiewicz JJ: Eradication of Helicobacter pylori with clarithromycin and omeprazole. Gut 1994, 35:323-326.
20. Bazzoli F, Zagari RM, Fossi S, Pozzato P, Alampi G, Simoni P, Sotili S, Roda A, Roda E: Short-term low dose triple therapy for the eradication of Helicobacter pylori. Eur J Gastroenterol Hepatol 1994, 6:773-777.
21. Goddard A, Logan R: One-week low-dose triple therapy: new standards for Helicobacter pylori treatment. Eur J Gastroenterol Hepatol 1995, 7:1-3.
22. Labenz J, Stolte M, Rühl GH, Becker T, Tillenburg B, Sollböhmer M, Börsch G: One-week low-dose triple therapy for eradication of Helicobacter pylori infection. Eur J Gastroenterol Hepatol 1995, 7:9-11.
23. Cover TL, Tummuru MK, Cao P, Thompson SA, Blaser MJ: Divergence of genetic sequences for the vacuolating cytotoxin among Helicobacter pylori strains. J Biol Chem 1994, 269:10566-10573. This report describes cloning and sequencing of the gene for the vacuolating toxin.
24. Telford JL, Ghiara P, Dell'Orco M, Comanducci M, Burroni D, Bugnoli M, Tecce MF, Censini S, Covacci A, Xiang Z, et al.: Gene structure of the Helicobacter pylori cytotoxin and evidence of its key role in gastric disease. J Exp Med 1994, 179:1653-1658. This report describes cloning and sequencing of the gene for the vacuolating toxin.
25. Phadnis SH, Ilver D, Janzon L, Normark S, Westblom TU: Pathological significance and molecular characterization of the vacuolating toxin gene of Helicobacter pylori. Infect Immun 1994, 62:1557-1565. This report describes cloning and sequencing of the gene for the vacuolating toxin.
26. Schmidt W, Haas R: Genetic analysis of the Helicobacter pylori vacuolating cytotoxin: structural similarities with the IgA protease type of exported protein. Mol Microbiol 1994, 12:307-319. This report describes cloning and sequencing of the gene for the vacuolating toxin.
27. Xiang Z, Censini S, Bayeli PF, Telford JH, Figura N, Rappuoli R, Covacci A: Analysis of expression of CagA and VacA virulence factors in 43 strains of Helicobacter pylori reveals that clinical isolates can be divided into two major types and that CagA is not necessary for expression of the vacuolating cytotoxin. Infect Immun 1995, 63:94-98.
28. Tummuru MK, Cover TL, Blaser MJ: Mutation of the cytotoxin-associated cagA gene does not affect the vacuolating cytotoxin activity of Helicobacter pylori. Infect Immun 1994, 62:2609-2613. Although cagA and vacA are usually coordinately expressed, this interesting manuscript suggests that inactivation of the cagA gene does not affect the expression of the vacuolating cytotoxin.
29. Sakagami T, Shimoyama T, O'Rourke J, Lee A: Back to the host: severity of inflammation induced by Helicobacter felis in different strains of mice [abstract 241]. Am J Gastroenterol 1994, 89:1345. This report, using the H. felis murine model, demonstrates the importance of the host response in the inflammatory response associated with Helicobacter infection.
30. Mohammadi M, Redline R, Nedrud J, Czinn S: Role of the host in pathogenesis of Helicabacter associated gastritis: H. felis infection of inbred mouse strains. Infect Immun 1996, in press. This report, using the H. felis murine model, demonstrates the importance of the host response in the inflammatory response associated with Helicobacter infection.
31. Crabtree JE, Wyatt JI, Trejdosiewicz LK, Peichl P, Nichols PH, Ramsay N, Primrose JN, Lindley IJD: Interleukin-8 expression in Helicobacter pylori infected, normal, and neoplastic gastroduodenal mucosa. J Clin Pathol 1994, 47:61-66.
32. Crowe SE, Alvarez L, Dytoc M, Hunt RH, Muller M, Sherman P, Patel J, Jin Y, Ernst PB: Expression of interleukin 8 and CD54 by human gastric epithelium after Helicobacter pylori infection in vitro. Gastroenterology 1995, 108:65-74.
33. Sharma SA, Tummuru MKR, Miller GR, Blaser MJ: Interleukin-8 response of gastric epithelial cell lines to Helicobacter pylori stimulation in vitro. Infect Immun 1995, 63:1681-1687.
34. Huang J, O'Toole PW, Doig P, Trust TJ: Stimulation of interleukin-8 production in epithelial cell lines by Helicobacter pylori. Infect Immun 1995, 63:1732-1738.
35. Evans DJJ, Evans DG, Takemura T, Nakano H, Lampert HC, Graham DY, Granger DN, Kvietys PR: Characterization of a Helicobacter pylori neutrophil-activating protein. Infect Immun 1995, 63:2213-2220.
36. Tufano MA, Rossano F, Catalanotti P, Liguori G, Capasso C, Ceccarelli MT, Marinelli P: Immunobiological activities of Helicobacter pylori porins. Infect Immun 1994, 62:1392-1399.
37. + T-cell clones from peripheral blood and gastric biopsies. Infect Immun 1995, 63:1102-1106.
38. Fan XJ, Chua A, Shahi CN, McDevitt J, Keeling PWN, Kelleher D: Gastric T lymphocyte responses to Helicobacter pylori colonisation. Gut 1994, 35:1379-1384. Evidence is accumulating that a TH1-type cellular immune response may play a role in the gastritis associated with Helicobacter infection.
39. Sharma SA, Miller GG, Perez-Perez GI, Gupta RS, Blaser MJ: Humoral and cellular immune recognition of Helicobacter pylori proteins are not concordant. Clin Exp Immunol 1994, 97:126-132.
40. Karttunen R, Karttunen T, Ekre H-PT, MacDonald TT: Interferon gamma and interleukin 4 secreting cells in the gastric antrum in Helicobacter pylori positive and negative gastritis. Gut 1995, 36:341-345. Evidence is accumulating that a TH1-type cellular immune response may play a role in the gastritis associated with Helicobacter infection.
41. Mohammadi M, Nedrud J, Redline R, Czinn S: Adoptive transfer of Helicobacter-specific lymphocytes enhances inflammation in mice [abstract]. Clin Immunol Immunopathol 1995, 76:S8. Evidence is accumulating that a TH1-type cellular immune response may play a role in the gastritis associated with Helicobacter infection.
42. Blanchard TG, Czinn SJ, Nedrud JG, Redline RW: Helicobacter-associated gastritis in SCID mice. Infect Immun 1995, 63:1113-1115.
43. Pappo J, Thomas WD, Kabok Z, Taylor NS, Murphy JC, Fox JG: Effects of oral immunization with recombinant urease on murine Helicobacter felis gastritis. Infect Immun 1995, 63:1246-1252.
44. Krakowka S, Eaton KA, Rings DM: Occurrence of gastric ulcers in gnotobiotic piglets colonized by Helicobacter pylori. Infect Immun 1995, 63:2352-2355.
45. Kleanthous H, Tibbitts T, Bakios TJ, Georgokopoulos K, Myers G, Ermak TH, Monath T: In vivo selection of a highly adapted H. pylori isolate and the development of an H. pylori mouse model for studying vaccine efficacy and attenuating lesions [abstract]. Gut 1995, 137:94. Part of a series of reports describing the adaptation of H. pylori to mice. The development of these H. pylori mouse models may allow investigators to study pathogenesis as well as vaccination.
46. Karita M, Li Q, Cantero D, Okita K: Establishment of a small animal model for human Helicobacter pylori infection using germ-free mouse. Am J Gastroenterol 1994, 89:208-213. Part of a series of reports describing the adaptation of H. pylori to mice. The development of these H. pylori mouse models may allow investigators to study pathogenesis as well as vaccination.
47. Marchetti M, Arico B, Burroni D, Figura N, Rappuoli R, Ghiara P: Development of a mouse model of Helicobacter pylori Infection that mimics human disease. Science 1995, 267:1655-1658. Part of a series of reports describing the adaptation of H. pylori to mice. The development of these H. pylori mouse models may allow investigators to study pathogenesis as well as vaccination.
48. McColm AA, Bagshaw J, Wallis J, McLaren A: Screening of anti-Helicobacter therapies in mice colonized with H. pylori [abstract]. Gut 1995, 137:92. Part of a series of reports describing the adaptation of H. pylori to mice. The development of these H. pylori mouse models may allow investigators to study pathogenesis as well as vaccination.
49. Aleljung P, Nilsson H-O, Wang X, Wadström T: The use of heparin-coated magnetic beads to monitor a Helicobacter pylori colonization in Balb-C mice [abstract]. Gut 1995, 137:93. Part of a series of reports describing the adaptation of H. pylori to mice. The development of these H. pylori mouse models may allow investigators to study pathogenesis as well as vaccination.
50. Michetti P, Corthesy-Thelaz I, Davin C, Haas R, Vaney A-C, Heitz M, Bille J, Kraehenbuhl JP, Saraga E, Blum AL: Immunization of Balb/c mice against Helicobacter felis infection with Helicobacter pylori urease. Gastroenterology 1994, 107:1002-1011. This is the first report using purified Helicobacter urease as an oral vaccine.
51. Ferrero RL, Thiberge J-M, Huerre M, Labigne A: Recombinant antigens prepared from the urease subunits of Helicobacter spp: evidence of protection in a mouse model of gastric Infection. Infect Immun 1994, 62:4981-4989.
52. Ferrero RL, Thiberge J-M, Kansau I, Wuscher N, Huerre M, Labigne A: The GroES homolog of Helicobacter pylori confers protective immunity against mucosal Infection in mice. Proc Natl Acad Sci U S A 1995, 92:6499-6503. This interesting report demonstrates that heat shock proteins can prevent Helicobacter infection when used as a vaccine antigen.
53. Lee CK, Weltzin R, Thomas WDJ, Kleanthous H, Ermak TH, Soman G, Hill JE, Ackerman SK, Monath TP: Oral immunization with recombinant Helicobacter pylori urease induces secretory IgA antibodies and protects mice from challenge with Helicobacter felis. J Infect Dis 1995, 172:161-172. In this report, in which recombinant urease was used as a vaccine in the H. felis model, several routes of administration were tried and correlates of protection were evaluated.
54. Dickinson BL, Clements JD: Dissociation of Escherichia coli heat-labile enterotoxin adjuvanticity from ADP-ribosyltransferase activity. Infect Immun 1995, 63:1617-1623.
55. Douce G, Trucotte C, Cropley I, Roberts M, Pizza M, Domenighini M, Rappuoli R, Dougan G: Mutants of Escherichia coli heat labile toxin lacking ADP-ribosyltransferase activity act as nontoxic, mucosal adjuvants. Proc Natl Acad Sci U S A 1995, 92:1644-1648.
56. Lee A, Chen M: Successful immunization against gastric infection with Helicobacter species: use of a cholera toxin B-subunit-whole-cell vaccine. Infect Immun 1994, 62:3594-3597. This report suggests that cholera toxin B subunit purified from holotoxin may be a safe, suitable adjuvant for Helicobacter vaccines.
57. Nedrud J, Blanchard T, Czinn S, Lycke N: Recombinant cholera toxin B subunit is not an adjuvant for oral immunization against Helicobacter felis in mice [abstract]. J Cell Biochem 1995, (suppl 19):261. This report confirms the observations made by Lee and Chen (Infect Immun 1994, 62:3594-3597) but further suggests that the adjuvant activity reported for cholera toxin B subunit may be associated with contaminating holotoxin, becuse recombinant cholera toxin B subunit did not have adjuvant activity.
58. Nedrud J, Blanchard T, Czinn S, Lycke N: Recombinant cholera toxin B subunit is not an adjuvant for oral immunization against Helicobacter felis in mice [abstract]. J Cell Biochem 1995, (suppl 19):261. This report confirms the observations made by Lee and Chen (Infect Immun 1994, 62:3594-3597) but further suggests that the adjuvant activity reported for cholera toxin B subunit may be associated with contaminating holotoxin, becuse recombinant cholera toxin B subunit did not have adjuvant activity.
59. Wilson AD, Clarke CJ, Stokes CR: Whole cholera toxin and B subunit act synergistically as an adjuvant for the mucosal immune response of mice to keyhole limpet haemocyanin. Scand J Immunol 1990, 31:443-451.
60. Tamura S-I, Yamanaka A, Shimohara M, Tomita T, Komase K, Tsuda Y, Suzuki Y, Nagamine T, Kawahara K, Danbara H, et al.: Synergistic action of cholera toxin B subunit (and Escherichia coli heat-labile toxin B subunit) and a trace amount of cholera whole toxin as an adjuvant for nasal influenza vaccine. Vaccine 1994, 12:419-426.
61. Doidge C, Gust I, Lee A, Buck F, Hazell S, Manne U: Therapeutic immunization against Helicobacter infection. Lancet 1994, 343:913-914. This exciting report suggests that vaccination may be useful as a treatment for chronic Helicobacter infection.
62. Corthesy-Theulaz I, Porta N, Glauser M, Saraga E, Vaney A-C, Haas R, Kraehenbuhl JP, Blum AL, Michetti P: Oral immunization with Helicobacter pylori urease B subunit as a treatment against Helicobacter infection in mice. Gastroenterology 1995, 109:115-121. This exciting report suggests that vaccination may be useful as a treatment for chronic Helicobacter infection.
63. Cuenca R, Blanchard T, Lee C, Monath R, Redline R, Nedrud J, Czinn S: Therapeutic immunization against Helicobacter mustelae infection in naturally infected ferrets. Gastroenterology 1995, 108:A78. This report extends the concept of therapeutic immunization to a naturally occurring endemic infection of ferrets by H. mustelae.